Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Historical Holders from Q3 2014 to Q3 2025

Symbol
SAGE
Type / Class
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Shares outstanding
62.7M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
26.7K
Holdings value
$494K
% of all portfolios
0%
Grand Portfolio weight change
-0.001%
Number of holders
4
Number of sells
-185
Average Value change %
0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $34.5M 4.43M BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.21% -33.6% $29.8M -$14.3M 3.27M -32.5% The Vanguard Group 30 Jun 2025
RTW INVESTMENTS, LP 4.9% $23.4M 3M RTW Investments, LP 31 Dec 2024
BB BIOTECH AG 1.9% $9.18M 1.18M BB Biotech AG 13 Jan 2025
MORGAN STANLEY 1.6% -82.9% $7.89M -$27.5M 1.01M -77.7% Morgan Stanley 28 Feb 2025
FMR LLC 0.8% -84.3% $3.9M -$28.2M 501K -87.8% FMR LLC 28 Feb 2025

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 26.7K $494K -$445M $8.94 4
2025 Q2 48.9M $446M -$15.8M $9.12 190
2025 Q1 51.8M $411M +$29.1M $7.95 196
2024 Q4 51.2M $278M -$6.2M $5.43 173
2024 Q3 51.3M $370M -$24.5M $7.22 171
2024 Q2 53.5M $581M -$70.1M $10.86 190
2024 Q1 58.4M $1.1B +$43.4M $18.74 199
2023 Q4 56.1M $1.22B -$60.8M $21.67 196
2023 Q3 58.8M $1.21B -$2.53M $20.58 192
2023 Q2 54.1M $2.54B +$53.8M $47.02 222
2023 Q1 53M $2.22B +$61.1M $41.96 210
2022 Q4 51.7M $1.97B +$219K $38.14 200
2022 Q3 51.5M $2.02B +$13.6M $39.16 182
2022 Q2 51.1M $1.65B +$39.7M $32.30 188
2022 Q1 49.9M $1.65B -$25.6M $33.10 190
2021 Q4 50.2M $2.14B +$29.2M $42.54 201
2021 Q3 49.1M $2.17B -$115M $44.31 215
2021 Q2 50.6M $2.88B -$159M $56.81 246
2021 Q1 53.1M $3.97B -$71.8M $74.85 254
2020 Q4 53.8M $4.65B +$61.8M $86.51 244
2020 Q3 53.7M $3.28B -$18.8M $61.12 224
2020 Q2 54M $2.25B +$2.12M $41.58 207
2020 Q1 55M $1.58B -$222M $28.72 213
2019 Q4 56M $4.04B -$418M $72.19 256
2019 Q3 58.3M $8.18B +$23.5M $140.29 273
2019 Q2 58.1M $10.6B +$990M $183.09 265
2019 Q1 56.3M $8.95B +$1.12B $159.05 258
2018 Q4 49.7M $4.76B +$3.5M $95.79 241
2018 Q3 49M $6.92B +$56.8M $141.25 272
2018 Q2 48.6M $7.61B +$162M $156.53 265
2018 Q1 47.5M $7.65B +$645M $161.07 243
2017 Q4 44.1M $7.26B +$681M $164.71 220
2017 Q3 39.3M $2.45B +$48.6M $62.30 168
2017 Q2 38.4M $3.06B +$50.6M $79.64 187
2017 Q1 37.9M $2.69B +$271M $71.07 185
2016 Q4 36.7M $1.88B -$50.1M $51.06 161
2016 Q3 37.8M $1.74B +$401M $46.05 150
2016 Q2 30.2M $911M +$29M $30.13 137
2016 Q1 29.1M $932M +$174M $32.06 138
2015 Q4 23.5M $1.37B +$157M $58.30 135
2015 Q3 27.2M $1.15B +$26.7M $42.32 126
2015 Q2 26.4M $1.93B +$372M $73.00 120
2015 Q1 21.5M $1.08B +$87.9M $50.23 90
2014 Q4 19.7M $723M +$22.9M $36.60 71
2014 Q3 18.9M $595M +$595M $31.50 50